iTeos Therapeutics, Inc.
ITOS
$7.19
-$0.33-4.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 177.89% | -47.37% | -59.30% | -100.00% | -95.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 177.89% | -47.37% | -59.30% | -100.00% | -95.29% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 177.89% | -47.37% | -59.30% | -100.00% | -95.29% |
| SG&A Expenses | -2.56% | 1.09% | 6.24% | 13.01% | 14.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.85% | 14.28% | 16.88% | 16.07% | 14.21% |
| Operating Income | -6.35% | -58.87% | -119.21% | -832.44% | -215.65% |
| Income Before Tax | -10.37% | -93.08% | -284.39% | -979.94% | -173.30% |
| Income Tax Expenses | 289.51% | 156.31% | 223.81% | 38.90% | -93.06% |
| Earnings from Continuing Operations | -19.33% | -96.71% | -280.67% | -1,274.65% | -216.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.33% | -96.71% | -280.67% | -1,274.65% | -216.54% |
| EBIT | -6.35% | -58.87% | -119.21% | -832.44% | -215.65% |
| EBITDA | -6.15% | -59.17% | -120.56% | -872.29% | -214.23% |
| EPS Basic | -5.10% | -83.13% | -278.99% | -1,261.23% | -215.72% |
| Normalized Basic EPS | 2.61% | -79.75% | -283.40% | -971.54% | -172.77% |
| EPS Diluted | -5.07% | -80.11% | -265.14% | -1,418.25% | -223.85% |
| Normalized Diluted EPS | 2.61% | -76.20% | -268.71% | -1,070.52% | -177.91% |
| Average Basic Shares Outstanding | 13.14% | 8.12% | 3.13% | 0.53% | 0.60% |
| Average Diluted Shares Outstanding | 13.14% | 6.69% | 0.31% | -3.59% | -5.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
